Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCND3 | P30281 | 2/20 | 0.33 |
| ▸ | CDK7 | P50613 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | CCNH | P51946 | 2/20 | 0.33 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899322 | 0.82 | TRPV1 (0.33) | DRD2DRD3KCNH2MEN1KMT2A | |
| SCHEMBL9899721 | 0.81 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2MAPTGAA | |
| SCHEMBL9900429 | 0.81 | ALDH1A1 (0.40) | DRD2DRD3KCNH2MEN1KMT2A | |
| SCHEMBL9899662 | 0.79 | ALDH1A1 (0.40) | DRD2DRD3KCNH2MEN1KMT2A | |
| SCHEMBL9898451 | 0.75 | KDM4E (0.45) | DRD2DRD3KCNH2KMT2ASMN1; SMN2 | |
| SCHEMBL15831836 | 0.73 | FFAR4 (0.49) | DRD2DRD3KCNH2MEN1KMT2A | |
| SCHEMBL9899784 | 0.73 | S100B (0.36) | DRD2DRD3KCNH2MEN1KMT2A | |
| SCHEMBL9897728 | 0.72 | ALDH1A1 (0.40) | KMT2AMAPTHSD17B10ALDH1A1LMNA | |
| SCHEMBL9946576 | 0.72 | PTGES (0.45) | — | |
| SCHEMBL9899663 | 0.71 | MAP4K4 (0.40) | DRD2DRD3KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649052-B1 | 2-AMINOBENZIMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2649052-B1 | 2-AMINOBENZIMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2649040-A1 | PROCESS FOR HOMOGENEOUSLY CATALYZED, HIGHLY SELECTIVE DIRECT AMINATION OF PRIMARY ALCOHOLS WITH AMMONIA TO PRIMARY AMINES WITH A HIGH VOLUME RATIO OF LIQUID PHASE TO GAS PHASE AND/OR HIGH PRESSURES | Evonik Degussa GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2649052-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | Boehringer Ingelheim International GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2614042-A1 | PROCESS FOR THE DIRECT AMINATION OF SECONDARY ALCOHOLS WITH AMMONIA TO GIVE PRIMARY AMINES | Evonik Degussa GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| WO-2012113475-A1 | PROCESS FOR THE DIRECT AMINATION OF ALCOHOLS USING AMMONIA TO FORM PRIMARY AMINES BY MEANS OF A XANTPHOS CATALYST SYSTEM | EVONIK DEGUSSA GMBH (DE) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012076560-A1 | PROCESS FOR HOMOGENEOUSLY CATALYZED, HIGHLY SELECTIVE DIRECT AMINATION OF PRIMARY ALCOHOLS WITH AMMONIA TO PRIMARY AMINES WITH A HIGH VOLUME RATIO OF LIQUID PHASE TO GAS PHASE AND/OR HIGH PRESSURES | EVONIK DEGUSSA GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076672-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012031884-A1 | PROCESS FOR THE DIRECT AMINATION OF SECONDARY ALCOHOLS WITH AMMONIA TO GIVE PRIMARY AMINES | EVONIK DEGUSSA GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309738-A1 | NOVEL COMPOUNDS | PTGER1, PTGS1, PTGES | DRD2 1238/4885DRD3 1178/4885KCNH2 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.